Original From: Genomeweb

Image Credit: MARCIO JOSE SANCHEZ/ASSOCIATED PRESS

PerkinElmer said on Wednesday that it has priced an offering of senior notes totaling $2.3 billion, providing the company with funds to help complete its planned acquisition of BioLegend.

PerkinElmer said it priced an offering of $500 million aggregate principal amount of 0.550 percent senior notes due 2023 at an issue price of 99.964 percent of the principal amount, as well as $800 million aggregate principal amount of 0.85 percent senior notes due 2024 at an issue price of 99.938 percent of the principal amount.

The Waltham, Massachusetts-based company also priced an offering of $500 million aggregate principal amount of 1.9 percent senior notes due 2028 at an issue price of 99.928 percent of the principal amount and $500 million aggregate principal amount of 2.25 percent senior notes due 2031 at an issue price of 99.697 percent of the principal amount.

The issuance of the notes is expected to close on Friday, and the notes will pay interest on a semi-annual basis.

PerkinElmer said the proceeds of the offering will provide some of the money for its $5.25 billion purchase of life science antibodies and reagents provider BioLegend, which was announced in July.

Last month, PerkinElmer entered into a $500 million credit facility to help fund the acquisition. A couple of weeks later, the firm signed an agreement for a $1.5 billion revolving credit facility.

Source：PerkinElmer Prices Senior Notes Offering